The Cigna Group (CI) Stock Analysis

Company Overview

The Cigna Group operates within the healthcare sector as a major provider of insurance and related products and services in the United States. Its business model is structured through two primary segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment specifically includes Pharmacy Benefit Services and Specialty and Car, while Cigna Healthcare focuses on direct-to-consumer health plans. This diversified approach allows the entity to serve a broad range of customers across the American healthcare landscape. In terms of scale, the company commands a market capitalization of $69.98B and generates annual revenue of $274.90B. The organization employs 65669 individuals, reflecting a massive operational footprint that necessitates significant capital allocation and management resources. The market cap figure of $69.98B indicates that the market values the company at a level consistent with its substantial revenue generation, though the price-to-sales ratio suggests a valuation discount relative to total revenue. The revenue figure of $274.90B places the company among the largest entities in the healthcare plans industry, demonstrating a dominant position that supports extensive network capabilities and negotiating power with providers and payers.

Financial Health

The company reported revenue of $274.90B for the trailing twelve months, with net income of $5.96B and EBITDA of $12.05B. The substantial gap between the $274.90B in revenue and the $5.96B in net income reveals a cost structure where operating expenses, including claims payments and administrative costs, consume a significant portion of top-line growth. This results in a profit margin of 2.2%, which, combined with an operating margin of 3.5% and a gross margin of 9.3%, highlights the capital-intensive nature of the health insurance business where low margins are typical due to high claims volatility and regulatory overhead. The generation of $9.77B in free cash flow provides the company with considerable financial flexibility to fund operations, manage liquidity, and potentially return capital to shareholders or service debt. Regarding liquidity and leverage, the company holds $8.73B in cash against total debt of $31.46B, resulting in a debt-to-equity ratio of 75.14. This leverage level, coupled with a current ratio of 0.85, indicates a balance sheet that is moderately leveraged and suggests that current assets are slightly insufficient to cover current liabilities without relying on external financing or asset sales. Return on Equity stands at 15.1%, while Return on Assets is 4.1%. These metrics reveal that the company generates returns on shareholder equity that are significantly higher than its returns on total assets, suggesting an efficient use of equity capital relative to the broader asset base, despite the high level of financial leverage.

Valuation Assessment

The valuation metrics show a trailing P/E ratio of 11.81 and a forward P/E of 7.83. The notable difference between these figures implies that the market expects earnings to grow significantly in the future, as the forward multiple is substantially lower than the trailing multiple, suggesting a discount applied to expected future profitability. The price-to-book ratio is 1.65, which indicates that the stock trades at a premium of approximately 65% over its book value, reflecting investor confidence in the company's intangible assets and future earnings potential despite low tangible asset backing. Alternative valuation metrics include a price-to-sales ratio of 0.25 and an EV/EBITDA of 7.63. The low price-to-sales ratio of 0.25 suggests the market is pricing the company on a conservative basis relative to its massive revenue stream, while the EV/EBITDA of 7.63 indicates a valuation that is relatively compressed compared to historical averages for healthcare insurers. The 52-week high is $350.00 and the 52-week low is $239.51. Without a specific current price provided in the source data, the relative position cannot be calculated as a percentage, but the range defines the volatility floor and ceiling for the security. The beta value is 0.23, which means the stock exhibits very low price volatility relative to the broader market, moving significantly less than the market average during periods of systemic risk or gain.

Growth & Income

Revenue growth is currently at 10.4% year over year, whereas earnings growth is at -9.3% year over year. This divergence indicates that earnings are growing much slower than revenue, or in this specific period, are declining while revenue expands, which implies that margin compression is occurring due to the large expense base or one-time costs affecting the bottom line. The company pays a dividend with a yield of 2.4% and maintains a payout ratio of 27.2%. This low payout ratio relative to the 15.1% return on equity suggests that the dividend is highly sustainable and that the company retains the majority of its earnings for reinvestment rather than distributing them all as cash. Given the negative earnings growth of -9.3%, the sustainability of the dividend is further supported by the conservative payout ratio, ensuring that distributions are not made at the expense of operational stability. Overall, the growth and income profile presents a scenario of strong top-line expansion offset by bottom-line headwinds, supported by a robust free cash flow of $9.77B and a reliable but modest dividend yield that does not rely on aggressive payout levels.